SHEPARD WILLIAM R

Director Shepard buys 1,469 shares at $297.38 for $437.1K; holdings surge 137.4% to 2.5K shares

William R. Shepard, CME Group director, executed 2 separate purchases totaling 1,469 shares for $437,101.02 at a blended average price of $297.38 on 2026-03-26, boosting his post-transaction holdings from 1.1K shares to 2.5K shares (a +137.4% increase). This represents a material accumulation of position. His prior trades at CME show a pattern of well-timed buys: 4 of his last 5 purchases at this ticker posted positive 90-day returns, with his most recent CME buys on 2025-12-30 yielding +6.9% and +4.1% over 90 days. The current purchase occurred when CME is trading at -8.8% from its 52-week high ($326.46), having declined -6.9% in the last 30 days, suggesting accumulation during a pullback. The company's fundamentals remain solid: $1.5B quarterly revenue, $908.0M net income, +6.4% annual revenue growth, and a P/E of 4.82 with $19.8B market cap.

CME Director William Shepard buys 262 shares in 2 transactions at $278.37 on 2025-12-30

William R. Shepard, Director at CME GROUP INC., made 2 separate purchases totaling 262 shares for $73,008.10 at a blended average price of $278.37 on 2025-12-30, increasing his holdings from 258,447 to 258,709 shares. The purchase occurred near the company's 52-week high of $290.71 (currently -7.2% below peak at $269.68), and comes at a valuation marked by a P/E of 5.04 and annual revenue growth of +9.9% with net income of $908.0M on quarterly revenue of $1,537,600,000.00. Shepard's track record across all tickers shows 20 prior buys with an average 90-day return of +5.3% and a 75.00% win rate; however, at CME specifically, 3 of 5 prior buys were well-timed at the 90-day mark, suggesting selective rather than consistent predictive accuracy at this name. The transaction size represents +0.1% relative to pre-transaction holdings, a modest addition to an already substantial position of 258.4K shares.

CME Director Shepard buys 274 shares for $72,671.67; holdings +12.5% to 2,466 shares

Director William R Shepard executed 2 separate purchases totaling 274 shares at a blended average price of $265.19, increasing his post-transaction holdings from 2,192 to 2,466 shares. His same-ticker history at CME shows 3 of 5 prior buys were well-timed at the 90-day mark, with his most recent CME purchase on 2025-01-16 yielding a 90d return of +14.7%, suggesting selective timing acumen at this security. The current price of $270.28 represents only -7.0% from the 52-week high, and CME fundamentals are strong with revenue of $1,692,000,000.00, net income of $1,025,100,000.00, and a P/E of 5.05. The purchase occurs when the stock is near recent highs and the insider has demonstrated a pattern of profitable entry timing on this specific ticker; investors should observe whether this accumulation aligns with continued execution or represents a departure from his prior discretionary trading discipline at CME.

Director Shepard buys 267 CME shares for $72,336.20; 5 of 5 prior CME buys well-timed with 90d gains.

Director William R. Shepard purchased 267 shares across 2 separate transactions totaling $72,336.20 at $270.53 per share on 2025-06-25, expanding his holdings by 12.2% to 2,454 shares. His prior trade history at CME is notably consistent: 5 of 5 previous buys posted positive 90-day returns ranging from +0.8% to +14.7%, indicating a pattern of well-timed entry points at this ticker. His broader cross-ticker track record reinforces this discipline, with 20 prior open-market buys averaging a 90-day win rate of 90.00% and an average 90-day return of +6.6%. The current stock price of $272.83 is only 6.2% below the 52-week high of $290.71 and has declined 4.0% over 30 days, yet Shepard's purchase at $270.53 aligns with his established pattern of disciplined accumulation at price points that historically produced gains within the 90-day window.

CME Director Shepard buys 274 shares for $71,994.65; 12.6% portfolio boost amid 4.4% 30-day rally.

William R. Shepard, a CME Group director, executed two separate open-market purchases totaling 274 shares for $71,994.65 ($262.62 blended average), expanding his shareholding by 12.6% from 2,169 to 2,443 shares. His prior buys at CME have demonstrated consistent timing: 3 of 3 measurable prior trades at this ticker posted positive 90-day returns (ranging from +0.8% to +12.4%), and his cross-ticker track record shows 87.50% win rate with +6.0% average 90-day return. The current purchase occurs during a period of upward momentum (30-day +4.4%, 90-day +12.1%) and within the stock's 52-week trading band (-1.8% from high), with CME's fundamentals showing $1.6B quarterly revenue, $912.8M net income, and a lean 4.89 P/E valuation at $17.5B market cap.

Director William R. Shepard purchases 1,429 shares of CME at $227.96 for $325,798.16, expanding holdings 142.5%

Director Shepard executed 2 separate purchases totaling 1,429 shares for $325,798.16 on 2025-01-16, increasing his post-transaction holdings to 2,432 shares from 1,003 shares (+142.5%). His prior 3 measurable trades at CME were all well-timed at the 90-day mark, with returns of +10.7%, +9.6%, and +9.6%, establishing a consistent pattern of favorable entry execution at this ticker. At a blended price of $227.96, this purchase occurs at 5.4% below the 52-week high of $246.02 and aligns with his demonstrated historical selectivity; his cross-ticker track record shows 16 prior buys with an 85.71% 90-day win rate and average 90d return of +5.1%. CME's fundamentals remain robust with $1.6B quarterly revenue, +11.2% annual growth, and a P/E of 4.75, providing a backdrop of operational strength for this substantial insider accumulation.

Director Shepard buys 276 shares of CME at $232.89; 4 of 5 prior CME buys showed strong 90d gains

Director William R. Shepard executed two separate purchases totaling 276 shares for $64,282.29 at $232.89, increasing his holdings to 255,436 shares. His prior trade history at CME is noteworthy: 4 of 5 earlier purchases over the past nine months were well-timed, with 90-day returns of +3.5%, +3.5%, +2.2%, and +2.2%, though one buy on 2024-03-26 returned -9.1% at the 90-day mark. The current purchase occurs while the stock is -5.9% from its 52-week high of $246.02 and down 2.7% over the past 30 days, though it has gained 2.8% over 90 days. CME's fundamentals remain solid with annual revenue growth of +11.2%, a P/E of 4.72, and net income of $912.8M on quarterly revenue of $1.6B. The insider's demonstrated pattern of well-timed accumulation at this ticker—particularly multiple purchases in June and September that subsequently delivered positive returns—provides context for assessing this purchase against recent price weakness.

Director William R Shepard bought 292 shares of CME at $218.50 for $63,945.11; holdings rise 14.2% to 2,360 shares.

Director William R Shepard executed 2 separate purchases totaling 292 shares for $63,945.11 on 2024-09-25, increasing his holdings by 14.2% from 2,067 to 2,360 shares. His prior buys at CME show a mixed pattern: 3 of 5 prior trades were well-timed at the 90-day mark, including his June 2024 purchases which delivered +10.7% 90-day returns and his January 2024 buy which returned +3.0%. However, his March 2024 purchases declined -9.1% over 90 days. The stock currently trades at $218.30, only 1.4% below its 52-week high and up 1.5% over the past 30 days and 11.0% over 90 days. CME's fundamentals remain robust with annual revenue growth of +11.2%, a low P/E of 4.45, and strong net income of $883.2M, providing foundational context for this accumulation.

Director Shepard bought 325 CME shares for $63,569.02 ($195.07) on 2024-06-25; stock down 9.2% in 30 days and 11.8% from 52-week high.

William R. Shepard, Director of CME GROUP INC., made 2 separate purchases totaling 325 shares for $63,569.02 at $195.07 on 2024-06-25, increasing his holdings from 254,565 to 254,891 shares. The timing is noteworthy given the stock's recent weakness: CME is down 9.2% over the last 30 days and 11.8% from its 52-week high of $221.35, trading at current price $195.20. Shepard's prior 5 trades at CME show mixed results, with 3 of 5 exhibiting well-timed entry points at the 90-day mark, suggesting some pattern of buying near temporary bottoms; his cross-ticker track record shows an 80.00% 90d win rate with an average 90d return of +3.1% on 10 prior buys. The modest purchase size (+0.1% of his post-transaction holdings of 254,891 shares) and the company's strong fundamentals—annual revenue growth of +11.2%, a P/E of 3.98, and net income of $855,200,000.00 in the latest quarter—offer some context, but the recent downtrend and small incremental position increase suggest neither significant conviction nor a material portfolio reshuffling.